MOVE: Understanding Vimseltinib for Tenosynovial Giant Cell Tumor
This observational study, called MOVE, aims to understand how vimseltinib is used in the real world by people with tenosynovial giant cell tumor (TGCT). Researchers want to learn about treatment patterns and how vimseltinib affects your quality of life. You can join if you have a TGCT diagnosis and are prescribed vimseltinib, or if the decision to start vimseltinib has been made. The study will track how long people take vimseltinib and when they might stop treatment, for up to 12 months. This study is currently unclear on its status and plans to enroll about 100 participants.
- Study design
- This is an observational study that will collect information from medical records without directly intervening in your care. It aims to enroll about 100 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track treatment duration and time to discontinuation for up to 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
At a glance
Conditions
NCT07075471
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Synexus Clinical Research, US INC
Wilmington, North Carolinastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Clinical Team · STUDY_DIRECTOR · Deciphera Pharmaceuticals, LLC
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Duration of Vimseltinib TreatmentBaseline up to 12 months
- Time to Discontinuation of VimseltinibBaseline to Discontinuation (Estimated up to 12 months)